Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1431908

Invasive Aspergillosis Complicated in Patient with Non-Small Cell Lung Cancer Harboring RET Fusion During Treatment with RET-TKIs: A Case Report and Literature Review

Provisionally accepted
Kaidiriye Setiwalidi Kaidiriye Setiwalidi Yimeng Li Yimeng Li Yuyan Ma Yuyan Ma Zhanpeng Hao Zhanpeng Hao Yujia Zhao Yujia Zhao Yuxin Zhang Yuxin Zhang Xuan Liang Xuan Liang Tao Tian Tao Tian Zhiping Ruan Zhiping Ruan Yu Yao Yu Yao *Xiao Fu Xiao Fu *
  • Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

The final, formatted version of the article will be published soon.

    Pralsetinib and selpercatinib have been approved as a specific tyrosine kinase inhibitor (TKI) for the treatment of patients with non-small cell lung cancer (NSCLC) harboring rearranged during transfection (RET) fusion and mutation. However, adverse events associated with pralsetinib and selpercatinib are not fully understood, especially in the real world. In this case, invasive aspergillosis that appeared concurrent with RET-TKIs targeted therapy is proposed to be an additional adverse drug reaction (ADR) that was not mentioned in previous reports. Here, we describe the process of clinical diagnosis and treatment of invasive aspergillosis, and attempt to explore its possible pathogenesis in association with RET-TKIs targeted therapy, with the aim of providing clinicians a more in-depth understanding of the ADR associated with RET-TKIs, as well as to prevent serious outcomes caused by reduction or discontinuation of anti-tumor therapy.

    Keywords: NSCLC, RET, Pralsetinib, Selpercatinib, invasive aspergillosis

    Received: 13 May 2024; Accepted: 28 Oct 2024.

    Copyright: © 2024 Setiwalidi, Li, Ma, Hao, Zhao, Zhang, Liang, Tian, Ruan, Yao and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yu Yao, Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
    Xiao Fu, Department of Medical Oncology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.